Yttrium 90 ibritumomab tiuxetan in lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 967-977

  Cheung, Matthew ^a,b   Haynes, Adam ^a   Stevens, Adrienne ^a   Meyer, Ralph ^a,c   Imrie, Kevin ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c Division of Hematology   (Canada)

Author keywords

Indolent lymphoma; Systematic review; Yttrium 90 ibritumomab tiuxetan; Zevalin

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DOSIMETRY; DYSPNEA; EVIDENCE BASED MEDICINE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; IMAGE ANALYSIS; INFECTION; MANTLE CELL LYMPHOMA; META ANALYSIS; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROAT IRRITATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RADIOMETRY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 33746300827     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600572582     Document Type: Review

References (43)

1. Armitage, J and Weisenburger, D. (1998) New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project J Clin Oncol, 16, pp. 2780-2795.
2. Horning, S. (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas Semin Oncol, 20, pp. 75-88.
3. McLaughlin, P and Grillo-Lopez, A and Link, B and et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program J Clin Oncol, 16, pp. 2825-2833.
4. Cartron, G and Watier, H and Golay, J and Solal-Celigny, P. (2004) From the bench to the bedside: Ways to improve rituximab efficacy Blood, 104, pp. 2635-2642.
5. Cheson, B. (2003) Radioimmunotherapy of non-Hodgkin lymphomas Blood, 101, pp. 391-398.
6. Browman, G and Levine, M and Mohide, E and et al. (1995) The practice guidelines development cycle: A conceptual tool for practice guidelines development and implementation J Clin Oncol, 13, pp. 502-512.
7. Witzig, T and White, C and Wiseman, G and et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma J Clin Oncol, 17, pp. 3793-3803.
8. Flinn, I and Kahl, B and Frey, E and et al. (2004) Dose finding trial of yttrium 90 (90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) Blood, pp. 104. (abstract)
9. Fung, H and Forman, S and Nademanee, A and et al. (2003) A new preparative regimen for older patients with aggressive CD20-positive B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM followed by autologous hematopoietic cell transplantation (AHCT): Targeted intensification without increased transplant-related toxicity Blood, pp. 102. (abstract)
10. Forero-Torres, A and Besh, S and Knox, S and et al. (2003) Higher doses of Rituxan alter pharmacokinetics and biodistribution of Zevalin but may increase responses; a preliminary report of a phase I study of Zevalin using a modified treatment regimen for relapsed or refractory CD20 + B-cell follicular/transformed non-Hodgkin's lymphoma Blood, pp. 102. (abstract)
11. Sweetenham, J and Dicke, K and Arcaroli, J and et al. (2004) Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma Blood, pp. 104.
12. Tsimberidou, A and Murray, J and O'Brien, S and et al. (2004) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome Cancer, 100, pp. 2195-2200.
13. Witzig, T and Gordon, L and Cabanillas, F and et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol, 20, pp. 2453-2463.
14. T and Flinn, I and Gordon, L and et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma J Clin Oncol, 20, pp. 3262-3269.
15. Wiseman, G and Gordon, L and Multani, P and et al. (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial Blood, 99, pp. 4336-4342.
16. Knox, S and Goris, M and Trisler, K and et al. (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma Clin Cancer Res, 2, pp. 457-470.
17. Morschhauser, F and Huglo, D and Martinelli, G and et al. (2004) Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/ refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial Blood, pp. 104. (abstract)
18. Oki, Y and Pro, B and Delpassand, E and et al. (2004) A phase II Study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) Blood, pp. 104. (abstract)
19. Radford, J and Ketterer, N and Sebban, C and et al. (2003) Ibritumomab tiuxetan (Zevalin) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular NHL in first remission: Interim analysis for safety of a multicenter, phase III clinical trial Blood, pp. 102. (abstract)
20. Liu, N and Keating, M and Albitar, M and et al. (2003) Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL Blood, pp. 102. (abstract)
21. Shipley, D and Spigel, D and Carrell, D and et al. (2004) Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial J Clin Oncol, 22, pp. 6519. (abstract)
22. Witzig, T and Wiseman, G and Geyer, S and et al. (2003) A phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma Blood, pp. 102. (abstract)
23. Winter, J and Inwards, D and Spies, S and et al. (2004) 90Y ibritumomab tiuxetan (Zevalin; 90YZ) doses higher than. 4 mCi/kg may be safely combined with high-dose beam and autotransplant: The role for dosimetry Blood, pp. 2004. (abstract)
24. Nademanee, A and Forman, S and Molina, A and et al. (2004) High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial J Clin Oncol, 22, pp. 6504. (abstract)
25. Vose, J and Bierman, P and Lynch, J and et al. (2003) Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT) Blood, pp. 102. (abstract)
26. Jacobs, S and McCook, B and Torok, F and et al. (2004) Evaluation of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in patients with non-Hodgkin's lymphoma (NHL) having previously received autologous stem cell transplant (ASCT) Blood, pp. 2004. (abstract)
27. Gordon, L and Witzig, T and Molina, A and et al. (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma Clin Lymphoma, 5, pp. 98-101.
28. Gordon, L and Witzig, T and Murray, J and et al. (2003) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular, or transformed B-cell NHL: Final results of a randomized controlled trial Proc Am Soc Clin Oncol, 22, pp. 576. (abstract)
29. Wiseman, G and Witzig, T and Murray, J and et al. (2000) Zevalin radioimmunotherapy (RIT) improves quality of life (QOL) in patients with low grade, follicular, or transformed non-Hodgkin's lymphoma (LG/F/T NHL) Blood, 96(11), pp. A3173.
30. Schilder, R and Molina, A and Bartlett, N and et al. (2004) Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia Cancer Biother Radiopharm, 19, pp. 478-481.
31. Emmanouilides, C and Czuczman, M and Revell, S and et al. (2004) Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan J Clin Oncol, 22, pp. 6696. (abstract)
32. Witzig, T and Gordon, L and Wiseman, G and et al. (2000) Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL), 96(11), pp. A3160.
33. Witzig, T and White, C and Gordon, L and et al. (2001) Zevalin radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL), 98(11), pp. A2539.
34. Witzig, T and White, C and Gordon, L and et al. (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma J Clin Oncol, 21, pp. 1263-1270.
35. Bartlett, N and Witzig, T and Gordon, L and et al. (2002) 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients, 21, pp. 14a, A51.
36. Emmanouilides, C and Murray, J and Vo, K and et al. (2003) Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hogdkin's lymphoma (NHL): Results with second-line therapy Blood, pp. 102. (abstract)
37. Czuczman, M and Emmanouilides, C and Witzig, T and et al. (2002) Multivariate analysis of prognostic factors correlated with response to 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma, 21, pp. 266a, A1062.
38. Gibson, A. (2002) Updated results of a phase III trial comparing ibritumomab tiuxetan with rituximab in previously treated patients with non-Hodgkin's lymphoma Clin Lymphoma, 3, pp. 87-89.
39. Nabhan, C and Peterson, L and Kent, S and et al. (2002) Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma Leuk Lymphoma, 43, pp. 2145-2149.
40. Schilder, R and Witzig, T and Gordon, L and et al. (2001) Zevalin radioimmunotherapy (RIT) for low grade, follicular, and CD20 + transformed non-Hodgkin's lymphoma (LG/F/T NHL) is effective even in patients with mild thrombocytopenia and poor prognostic factors Pro Am Soc Clin Oncol, 20, pp. 2366, A2696.
41. Wiseman, G and Leigh, B and Dunn, W and et al. (2003) Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy Cancer Biother Radiopharma, 18, pp. 253-258.
42. Wiseman, G and White, C and Sparks, R and et al. (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Crit Rev Oncol Hematol, 39, pp. 181-194.
43. Conti, P and White, C and Pieslor, P and et al. (2004) Incidence of altered biodistribution detected by indium 111 (111In) imaging prior to yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy: results from a Zevalin imaging registry Blood, pp. 104. (abstract)